You will be required to complete an information form for each patient. Select this option to schedule both a 1st and 2nd dose appointment. The 1st dose appointment will be scheduled for the selected time. Don't forget to schedule a return appointment for the 2nd dose three weeks (21 days) later.

You will be required to complete an information form for each patient. Select this to schedule only a 2nd dose Pfizer appointment.

You will be required to complete an information form for each patient. Select this option to schedule both a 1st and 2nd dose appointment. The 1st dose appointment will be scheduled for the selected time. Remember to schedule a return appointment for the 2nd dose time three weeks (21 days) later.

You will be required to complete an information form for each patient. Select this to schedule only a 2nd dose Pfizer appointment.

You will be required to complete an information form for each patient. Note: On May 5, 2022 the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine. This decision is related to the risk of thrombosis with thrombocytopenia syndrome (TTS), a syndrome of rare and potentially life-threatening blood clots in combination with low levels of blood platelets with onset of symptoms approximately one to two weeks following administration of the Janssen COVID-19 Vaccine,

You will be required to complete an information form for each patient. To learn more about this vaccine:

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine

You will be required to complete an information form for each patient. Note: On May 5, 2022 the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine. This decision is related to the risk of thrombosis with thrombocytopenia syndrome (TTS), a syndrome of rare and potentially life-threatening blood clots in combination with low levels of blood platelets with onset of symptoms approximately one to two weeks following administration of the Janssen COVID-19 Vaccine,